The RISE-IIP study, which was evaluating efficacy and safety of ADEMPAS (riociguat) in patients with symptomatic PH-IIP, has been terminated early, because interim results of RISE-IIP showed an increased risk of mortality and serious adverse events among patients receiving ADEMPAS compared to those receiving placebo. The available data indicate that the use of ADEMPAS in patients with PH-IIP presents greater risks than benefits.
RecallTracker